Methoxyamine
- Generic Name
- Methoxyamine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- CH5NO
- CAS Number
- 67-62-9
- Unique Ingredient Identifier
- 9TZH4WY30J
- Indication
Investigated for use/treatment in cancer/tumors (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Stage III Lung Cancer AJCC v8Lung AdenocarcinomaLung Large Cell CarcinomaLung Non-Squamous Non-Small Cell Carcinoma
- Interventions
- Drug: CarboplatinDrug: CisplatinProcedure: Computed TomographyBiological: DurvalumabProcedure: FDG-Positron Emission TomographyProcedure: Magnetic Resonance ImagingDrug: MethoxyamineDrug: PemetrexedRadiation: Radiation Therapy
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT05198830
- Locations
- 🇺🇸
Keck Medicine of USC Buena Park, Buena Park, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸City of Hope at Irvine Lennar, Irvine, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath